Phage therapy in antibiotic resistant pneumonia: immunomodulation or redistribution?

Our report concerns the observations made during the treatment of pneumonia with individually selected bacteriophages in HCAI patients on mechanical ventilation. 19 patients on mechanical ventilation whose condition was complicated by antibiotic-resistant pneumonia were examined. The treatment of patients was supplemented with phage therapy, bacteriophages were selected individually for each patient, taking into account the microbial etiology of the disease (Pseudomonas aeruginosa, Кlebsiella pneumoniae, Acinetobacter baumanii). Immunophenotyping of blood lymphocytes was carried out using 2-3-parameter flow cytometry. The functional activity of blood leukocytes was assessed by their ability to produce IFNα and IFNγ during cultivation. The level of interferons production in supernatants collected after cultivation was quantitatively evaluated both by their concentration (ELISA, reagents from “Vector-Best-Europe”, Russia) and by their biological activity. Statistical processing of the results was carried out using the Statistica 6 program according to the nonparametric Mann-Whitney U-test. In the course of successful phage therapy with individually selected bacteriophages overcoming of lymphopenia (if there was one) and an increase in both the number and functional activity of peripheral blood lymphocytes in all patients with pneumonia observed are noted. The relationship between the microbial load (mono- or mixed infection, the number of CFU pathogens of pneumonia, the need for repeated courses of phage therapy) and the degree of deficiency in one or another subpopulation of lymphocytes was not detected. Activation of the immune system achieved after one course of phage therapy was maintained for at least 3 weeks after phage administration was discontinued.

1. Aleshkin A.V., Svetoch E.A., Volozhantsev N.V., Kiseleva I.A., Rubalsky E.O., Ershova O.N., Novikova L.I. Innovative directions for the use of bacteriophages in the field of sanitary and epidemiological welfare of the population of the Russian Federation // Bacteriology.2016; 1(1): 22-31. [doi: 10.20953/2500-1027-2016-1-22-31]

2. Determination of interferon status, as an indicator of non-specific resistance of the human body/ Practical recommendations of the Association of laboratory and organizations "Federation of Laboratory Medicine",еdited by academician of RAS, Professor F. I. Ershov, Москва, 2018, 26 с. https://fedlab.ru/upload/medialibrary/bc9/Prakt-rek-IFN-status_-FLM_-2018.pdf

3. Patent RU 2 664 681 C1 of 2018.08.21. Method of treatment of infection related to the provision of medical assistance caused by a causative agent or pathogens with multiple drug resistance. Aleshkin A.V., Aleshkin V.A., Ershova O.N., Bochkareva S.S. Shkoda A.S., VajnshtokI.I.,Vedyashkina S. G., Mitrokhin S.D., Kalacheva O.S., Orlova O.E., Kiseleva I.A., Rubalskij E.O., Zulkarneev E. R. https://yandex.ru/patents/doc/RU2664681C1_20180821

4. Reshedko GK, Ryabkova EL, Krechikova OI, Sukhorukova MV, Shevchenko OV, Edelstein MV, Kozlov R.S.. Antibiotic resistance of Gram-negative causative agents of nosocomial infections in the ICU of multidisciplinary hospitals in Russia. Clinical microbiology and antimicrobial chemotherapy. 2008; 10 (2): 96-112. https://cmac-journal.ru/en/publication/2008/2/cmac-2008-t10-n2-p163/cmac-2008-t10-n2-p163.pdf

5. Aarestrup FM. 2015 The livestock reservoir for antimicrobial resistance: a personal view on changing patterns of risks, effects of interventions and the way forward.Phil. Trans. R. Soc. B 370: 20140085 http://dx.doi.org/10.1098/rstb.2014.0085.

6. Ardain A., Marakalala M.J., Leslie A. Tissue-resident innate immunity in the lung/ Immunology, 2020, Vol.159, no. 3, pp.245-256. [doi: 10.1111/imm.13143]

7. Bochkareva S.S., Aleshkin A.V., Ershova O.N. Novikova L.I., Karaulov A.V., Kiseleva I.A., Zulkarneev E. R., ., Rubalskij E.O., Zeigarnik M.A. Anti-phage antibody response in phage therapy against healthcare-associated infections (HAIs). Infection diseases, 2017,V15, №1, p. 35-40. [doi: 10.20953/1729-9225-2017-1-35-40]

8. Dąbrowska K. Phage therapy: What factors shape phage pharmacokinetics and bioavailability? Systematic and critical review.// Med Res Rev. 2019 Sep;39(5):2000-2025 [doi: 10.1002/med.21572]

9. Ge C., Monk I.R., Pizzolla A., Wang N., Bedford J.G., Stinear T.P., Westall G.P., Wakim L.M. Bystander Activation of Pulmonary Trm Cells Attenuates the Severity of Bacterial Pneumonia by Enhancing Neutrophil Recruitment. Cell Rep., 2019, Vol.29, no. 13, pp.4236-4244.e3. [doi: 10.1016/j.celrep.2019.11.103.]

10. Górski A., Międzybrodzki R., Borysowski J., Dąbrowska K., Wierzbicki P., Ohams M., Korczak-Kowalska G., Olszowska-Zaremba N., Łusiak-Szelachowska M., Kłak M., Jończyk E., Kaniuga E., Gołaś A., Purchla S., Weber-Dąbrowska B., Letkiewicz S., Fortuna W., Szufnarowski K., Pawełczyk Z., Rogóż P., Kłosowska D. Phage as a modulator of immune responses: practical implications for phage therapy. Adv Virus Res., 2012, Vol. 83, pp.41-71. [doi: 10.1016/B978-0-12-394438-2.00002-5.]

11. Górski A, Jończyk-Matysiak E, Łusiak-Szelachowska M, Międzybrodzki R, Weber-Dąbrowska B, Borysowski J. 2018. Phage therapy in allergic disorders? Exp Biol Med (Maywood). 2018 Mar; 243(6):534-537 [ doi: 10.1177/1535370218755658]

12. Górski A, Jończyk-Matysiak E, Międzybrodzki R, Weber-Dąbrowska B, Borysowski J. 2018. "Phage Transplantation in Allotransplantation": Possible Treatment in Graft-Versus-Host Disease? Front Immunol, 9: 941. [ doi: 10.3389/fimmu.2018.00941]

13. Lai H.C., Chang C.J., Lin C.S., Wu T.R., Hsu Y.J., Wu T.S., Lu J.J., Martel J., Ojcius D.M. , Ku C.L., Young J.D., Lu C.C.. NK Cell-Derived IFN-γ Protects against Nontuberculous Mycobacterial Lung Infection. J Immunol., 2018, Vol.201, no. 5, pp.1478-1490. [doi: 10.4049/jimmunol.1800123.]

14. Moser C., Jensen P.O., Kobayashi O., Hougen H.P., Song Z., Rygaard J.,Kharazmi A., H by N. Improved outcome of chronic Pseudomonas aeruginosa lung infection is associated with induction of a Th1-dominated cytokine response. Clin Exp Immunol., 2002, Vol.127, no. 2, pp.206-213. [doi:10.1046/j.1365-2249/2002.01731.x]

15. Van Belleghem J.D., Dąbrowska K., Vaneechoutte M., Barr J.J., Bollyky P.L. Interactions between Bacteriophage, Bacteria, and the Mammalian Immune System. Viruses., 2018, Vol.11, no. 1, pii: E10. [doi: 10.3390/v11010010.]